Brad Canino
Stock Analyst at Guggenheim
(2.85)
# 1,397
Out of 5,127 analysts
22
Total ratings
42.11%
Success rate
2.78%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Brad Canino
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| GLTO Galecto | Maintains: Buy | $32 → $36 | $20.37 | +76.73% | 2 | Dec 8, 2025 | |
| BDTX Black Diamond Therapeutics | Downgrades: Neutral | n/a | $2.78 | - | 2 | Dec 4, 2025 | |
| NUVL Nuvalent | Maintains: Buy | $125 → $155 | $102.67 | +50.97% | 2 | Nov 18, 2025 | |
| PYXS Pyxis Oncology | Maintains: Buy | $5 → $7 | $1.45 | +382.76% | 2 | Nov 4, 2025 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $90 | $74.98 | +20.03% | 1 | Nov 3, 2025 | |
| SMMT Summit Therapeutics | Reiterates: Buy | $40 | $18.83 | +112.43% | 2 | Oct 22, 2025 | |
| CGON CG Oncology | Initiates: Buy | $90 | $41.93 | +114.64% | 1 | Oct 8, 2025 | |
| OLMA Olema Pharmaceuticals | Initiates: Buy | $20 | $25.57 | -21.78% | 1 | Oct 8, 2025 | |
| CELC Celcuity | Initiates: Buy | $110 | $104.67 | +5.09% | 1 | Sep 22, 2025 | |
| ORIC ORIC Pharmaceuticals | Assumes: Buy | $18 | $8.45 | +113.02% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $15 | $8.00 | +87.50% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $2.19 | +265.30% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $72 | $13.91 | +417.61% | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | n/a | $9.55 | - | 1 | Sep 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $55 | $23.10 | +138.10% | 1 | Mar 31, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $30 | $44.15 | -32.05% | 2 | Mar 31, 2021 |
Galecto
Dec 8, 2025
Maintains: Buy
Price Target: $32 → $36
Current: $20.37
Upside: +76.73%
Black Diamond Therapeutics
Dec 4, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.78
Upside: -
Nuvalent
Nov 18, 2025
Maintains: Buy
Price Target: $125 → $155
Current: $102.67
Upside: +50.97%
Pyxis Oncology
Nov 4, 2025
Maintains: Buy
Price Target: $5 → $7
Current: $1.45
Upside: +382.76%
Kymera Therapeutics
Nov 3, 2025
Assumes: Buy
Price Target: $90
Current: $74.98
Upside: +20.03%
Summit Therapeutics
Oct 22, 2025
Reiterates: Buy
Price Target: $40
Current: $18.83
Upside: +112.43%
CG Oncology
Oct 8, 2025
Initiates: Buy
Price Target: $90
Current: $41.93
Upside: +114.64%
Olema Pharmaceuticals
Oct 8, 2025
Initiates: Buy
Price Target: $20
Current: $25.57
Upside: -21.78%
Celcuity
Sep 22, 2025
Initiates: Buy
Price Target: $110
Current: $104.67
Upside: +5.09%
ORIC Pharmaceuticals
Sep 4, 2025
Assumes: Buy
Price Target: $18
Current: $8.45
Upside: +113.02%
Sep 4, 2025
Assumes: Buy
Price Target: $15
Current: $8.00
Upside: +87.50%
Sep 4, 2025
Initiates: Buy
Price Target: $8
Current: $2.19
Upside: +265.30%
Sep 4, 2025
Initiates: Buy
Price Target: $72
Current: $13.91
Upside: +417.61%
Sep 4, 2025
Initiates: Neutral
Price Target: n/a
Current: $9.55
Upside: -
Mar 31, 2021
Initiates: Outperform
Price Target: $55
Current: $23.10
Upside: +138.10%
Mar 31, 2021
Initiates: Outperform
Price Target: $30
Current: $44.15
Upside: -32.05%